Trial Profile
Single oral dose study of GS 9256 in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2011
Price :
$35
*
At a glance
- Drugs GS 9256 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 16 Feb 2011 New trial record
- 01 Nov 2010 Results presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases